Oramed Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the final voting results from the 2026 Annual Meeting of Stockholders held on September 15, 2026. Oramed Pharmaceuticals Inc. is a Delaware corporation with its principal executive offices in New York, New York. The company's common stock trades on the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Stockholders voted on six proposals at the Annual Meeting. All substantive proposals were approved:
- Proposal 1 (Re-election of Directors): All six nominees were re-elected. Notable "Against" votes included Dr. Daniel Aghion (4,769,203), Dr. Arie Mayer (5,648,636), and Benjamin Shapiro (5,859,953).
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Kesselman & Kesselman as the independent registered public accounting firm for the 2026 fiscal year.
- Proposal 3 (Stock Incentive Plan Amendment): Stockholders approved an amendment to increase the number of shares authorized for issuance under the 2019 Stock Incentive Plan by 3,000,000, bringing the total to 12,500,000 shares.
- Proposal 4 (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-advisory basis.
- Proposal 5 (Say-on-Pay Frequency): Stockholders selected a three-year frequency for future say-on-pay votes. The Board has determined to hold these votes every three years until the next required advisory vote.
- Proposal 6 (Adjournment): This proposal was rendered moot as sufficient votes were cast to approve Proposals 1 through 5.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operational outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the significant number of "Against" votes for certain directors and the stock plan amendment.
- Confirm the impact of the 3,000,000 share increase in the Stock Incentive Plan on potential future dilution.
- Review the company's subsequent filings for any operational updates or financial results not included in this governance-focused report.
- Note the high volume of broker non-votes (7,538,073) on director elections and the stock plan amendment, indicating shares held by brokers without voting instructions on those specific matters.